H2020Индивидуална стипендия2016–2018

RECORDER · Rare Earth based Upconversion Luminescent Nanomaterials as novel bioprobes for the detection of cardiac biomarkers

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2016-07-13 → 2018-08-25
Финансиране от ЕС: 195 455 €
Участници: 1
Схема: MSCA-IF-EF-ST

Линиите свързват координатора с партньорите.

Накратко на български

Наночастици от редки земни елементи се използват за откриване на специфични биомаркери в сърцето чрез светлинни сигнали. Това помага за създаването на по-точни системи за диагностика и визуализация на сърдечни заболявания.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Rare Earth based Upconversion Luminescent Nanomaterials as novel bioprobes for the detection of cardiac biomarkers

The objectives of the project include the synthesis of upconversion nanoparticles (UCNPs) and adopting the application of upconversion fluorescence phenomena for the detection of cardiac biomarkers and fabrication of a multianalyte system. As the part of achieving the final target of biosensing using the phenomena of upconversion, we have developed cubic as well as hexagonal UCNPs with very high fluorescence emission when excited using near infrared (NIR) radiation. UCNPs have been synthesised with variation in host/sensitizer/activator and were optimised with respect to photoluminescence and were correlated with structural features including nano size distribution. The main materials chemistry part including synthesis of upconversion particles (using solution, hydrothermal and solvothermal methods) and optimisation of conjugation of bioreceptors such as reduced antibodies and Affimers to selected UCNPs has successfully been carried out. Silica substrates were also successfully fabricated. The biosensing of selected markers were done using the upconversion phenomena where a limit of detection of 10nM have been achieved. Attempts are going on to reduce the detection limit in the range 0.1-0.01 nM and even pM level. Different attempts are going on in order to use the substrate based detection technology for multimarker detection. Possibilities of using UCNPs for imaging were also attempted as a part of application of UCNPs.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Cardiovascular diseases (CVD) which include acute myocardial infarction (AMI) and stroke are the main causes of premature deaths in the EU and in Asian countries including India. Researchers have identified and reported that biomarkers can provide advance information about cardiac dysfunction which leads to acute myocardial infarction (AMI) and stroke. However technologies for sensitive and accurate detection of CVD biomarkers are not available. The nature of the CVD also demands efficient simultaneous detection of these biomarkers that the current approaches are incapable of. RECORDER aims to develop a novel biophotonic sensor methodology and technology concept for unambiguous detection of multiple biomarkers, which give confidence in the early diagnosis of CVD that in the longer term can be developed for point of care (POC) applications. The underpinning sensor principle in RECORDER is based on measureable fluorescence resonance energy transfer (FRET) from rare earth (RE) doped nanoparticles under infrared laser (wavelengths >900 nm) excitation known as upconversion fluorescence to acceptor nanoparticle with specific absorptions in the presence of very small concentrations (1-0.01ng/mL) of biomarkers. The investigation of parameters including sensitivity, specificity and speed of detection of CVD biomarkers such as cardiac troponin (mainly, cTnI), heart fatty acid binding protein (H-FABP) lipoprotein-associated phospholipase A(2) (Lp-PLA2) and myoglobin (Mb) based on upconversion and upconversion fluorescence energy transfer (UC-FRET) to overcome large noise in signal due to autofluorescence if excited with ultraviolet or visible wavelengths as in conventional FRET, will be a highly novel approach. UC-FRET applied to detect CVD biomarkers in this project will lead to a novel platform technology that will revolutionize biomarker analysis in a cost effective manner for better patient management in hospitals, primary health care and in the long term at POC.

Оригинален текст от CORDIS (на английски).

Участници

UNIVERSITY OF LEEDS · LeedsКоординаторОбединеното кралство